It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Pharmacogenetic studies have shown involvement of cytochrome P450 enzymes in the metabolism of psychotropic drugs. However, expression and activity on endogenous substrates in the brain may underlie a constitutive role of these enzymes beyond drug metabolism. CYP2C19, which is expressed in the human fetal brain during neurodevelopment, shows affinity for endogenous compounds including monoaminergic neurotransmitters, steroid hormones, and endocannabinoids. In this study (N = 608), we looked at the genetic polymorphism of CYP2C19 and its potential associations with structural phenotypes of subcortical brain volume with structural imaging. Using two independent volume estimation techniques, we found converging evidence for a positive association between CYP2C19 activity scores, as inferred from the genotype, and basal ganglia and hippocampal volume. This association was present only in female individuals, raising the possibility that effects on brain morphology may arise through a mechanism involving the metabolism of estrogen steroids.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 University Hospital of RWTH Aachen, Institute of Clinical Pharmacology, Aachen, Germany (GRID:grid.412301.5) (ISNI:0000 0000 8653 1507); Federal Institute for Drugs and Medical Devices, Research Division, Bonn, Germany (GRID:grid.414802.b) (ISNI:0000 0000 9599 0422)
2 Federal Institute for Drugs and Medical Devices, Research Division, Bonn, Germany (GRID:grid.414802.b) (ISNI:0000 0000 9599 0422)
3 University of Ulm, Psychiatry and Psychotherapy Clinic III, Ulm, Germany (GRID:grid.6582.9) (ISNI:0000 0004 1936 9748)
4 University of Ulm, Psychiatry and Psychotherapy Clinic III, Ulm, Germany (GRID:grid.6582.9) (ISNI:0000 0004 1936 9748); University of Innsbruck, Institute of Psychology, Innsbruck, Austria (GRID:grid.5771.4) (ISNI:0000 0001 2151 8122)